FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
MENLO PARK, Calif., Feb. 01, 2018 -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the first quarter ended December 31, 2017 on February 8, 2018 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and report on recent progress.
Conference Call and Webcast Details
Investors and analysts can access the conference call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 7046249. The conference call will also be available via a live audio webcast which may be accessed here, or by visiting the Investors section of Corium's website at http://ir.coriumgroup.com/events-and-presentations. The webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumintl.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Source: Corium
Investor and Media Contact:
SMP Communications
Susan Pietropaolo
[email protected]
(201) 923-2049
